Publications by authors named "Burkhard Matthes"

Claim this Profile
C
Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
Friedemann Schad, Anja Thronicke, Megan L Steele, Antje Merkle, Burkhard Matthes, Harald Matthes

PLoS One· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids.
Nikolaj Frost, Jens Kollmeier, Daniel Misch, Claudia Vollbrecht, Christian Grah, Burkhard Matthes

Clin Lung Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On L: A Multicenter Real-World Study.
Anja Thronicke, Burkhard Matthes, Philipp von Trott, Friedemann Schad, Christian Grah

Integr Cancer Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma.
Nikolaj Frost, Jens Kollmeier, Claudia Vollbrecht, Christian Grah, Burkhard Matthes

Transl Lung Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
Anja Thronicke, Thomas Reinhold, Philipp von Trott, Christian Grah, Burkhard Matthes, Harald Matthes

PLoS One· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Patients with Lung Cancer Applying Integrative Oncology Concepts in a Certified Cancer Centre.
Anja Thronicke, Phillipp von Trott, Matthias Kröz, Christian Grah, Burkhard Matthes

Evid Based Complement Alternat Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
Friedemann Schad, Anja Thronicke, Megan L Steele, Antje Merkle, Burkhard Matthes, Harald Matthes

PLoS One· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.
Anja Thronicke, Megan L Steele, Christian Grah, Burkhard Matthes, Friedemann Schad

BMC Complement Altern Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network Oncology (NO)--a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine.
Friedemann Schad, Jan Axtner, Antje Happe, Thomas Breitkreuz, Constantin Paxino, Burkhard Matthes, Harald Matthes

Forsch Komplementmed· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biotechnological production and bioactivities of mollisin and two new, structurally related fungal naphthoquinone metabolites.
Siegfried Johne, Roland Watzke, Wolfram Meusel, Ute Möllmann, Albert Härtl, Burkhard Matthes

Chem Biodivers· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis